Home > Oncology > Liquid-biopsy testing in prostate cancer may lead to inappropriate treatment

Liquid-biopsy testing in prostate cancer may lead to inappropriate treatment


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA Oncology
Reuters Health - 11/11/2020 - In men with prostate cancer, cell-free DNA (cfDNA) testing may be confounded by clonal hematopoiesis (CHIP) gene variants, leading some patients to be treated inappropriately with poly(ADP) ribose polymerase (PARP) inhibitors. "Our study highlights an important limitation of most current cfDNA or 'liquid biopsy' testing for men with prostate cancer," Dr. Colin C. Pritchard of the University of Washington, in Seattle, told Reuters Health by email. "We found that blood-cell mutations were commonly detected in blood plasma, and that these mutations could be misinterpreted as coming from prostate cancer. The results have important implications for guiding therapy with a newer class of drugs called PARP inhibitors." "Almost half the time that mutations related to (U.S. Food and Drug Administration)-approved indications for PARP inhibitor eligibility were detected in cfDNA, they were derived from blood-cell clonal hematopoiesis, and not relat...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on